PRODUCT RANGE

ixabepilone) for Injection

Taj Group of Companies TAJ PHARMACEUTICALS LTD.

Metastatic Breast Cancer Treatment

For Advanced Breast Cancer Patients (ixabepilone) for Injection

Wempra the treatment


aggressive metastatic or locally

advanced breast cancer no longer responding to currently

available chemotherapies.



WEMPRA (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally advanced breast cancer.



WEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.



For Advanced Breast Cancer Patients (ixabepilone) for Injection